SH2D2A and neoplasm: The improved tumor resistance observed in SH2D2A-deficient Id-specific TCR-transgenic mice could thus be due to alteration in Lck activity mimicking reduced Lck levels, which results in persistence of effector T cells and improved tumor response as described by Caserta and colleagues [38].